Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovita Biological Technology Co has a current ratio of 15.58. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Innovita Biological Technology Co's Current Ratio or its related term are showing as below:
SHSE:688253'
s Current Ratio Range Over the Past 10 Years
Min: 2.06 Med: 11.69 Max: 20.83
Current: 15.58
During the past 8 years, Innovita Biological Technology Co's highest Current Ratio was 20.83. The lowest was 2.06. And the median was 11.69.
SHSE:688253's Current Ratio is ranked better than 87.31% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs SHSE:688253: 15.58
Innovita Biological Technology Co (SHSE:688253) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Innovita Biological Technology Co Current Ratio Related Terms
Innovita Biological Technology Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovita Biological Technology Co Current Ratio Chart
SHSE:688253 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Innovita Biological Technology Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovita Biological Technology Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovita Biological Technology Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Innovita Biological Technology Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovita Biological Technology Co (SHSE:688253) has a Current Ratio of 15.58 as of Mar. 2026. This is 33% above median its historical median of 11.69. Over the past decade, Innovita Biological Technology Co's Current Ratio has ranged from 2.06 to 20.83. According to the industry distribution chart, Innovita Biological Technology Co ranks #179 out of 1411 companies in the Biotechnology industry, placing it in the top 12.7%.
Is Innovita Biological Technology Co's Current Ratio too high?
Innovita Biological Technology Co's current Current Ratio of 15.58 is 33% above median its 10-year median of 11.69. Over the past 10 years, this metric has ranged from a low of 2.06 to a high of 20.83. The Biotechnology industry median Current Ratio is 3.88. Innovita Biological Technology Co's value of 15.58 is 301.5% above this industry median. Based on the distribution chart, Innovita Biological Technology Co ranks #179 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Innovita Biological Technology Co has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innovita Biological Technology Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovita Biological Technology Co ranks #179 out of 1411 companies for Current Ratio. This places Innovita Biological Technology Co in the top 13% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. Innovita Biological Technology Co's value of 15.58 is 301.5% above this benchmark. Historically, Innovita Biological Technology Co's own Current Ratio has ranged from 2.06 to 20.83 over the past decade. While the company's 10-year median is 11.69 vs. the industry median of 3.88, Innovita Biological Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovita Biological Technology Co's current Current Ratio of 15.58 is 301.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovita Biological Technology Co's current Current Ratio is 15.58, which is 33% above median its own 10-year median of 11.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovita Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Innovita Biological Technology Co (SHSE:688253) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥20.48, compared to a current price of ¥58.92 — trading 187.7% above its estimated fair value. The current Current Ratio is 15.58, which is 33% above median its 10-year median of 11.69 and 301.5% above the Biotechnology industry median of 3.88. Innovita Biological Technology Co's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Innovita Biological Technology Co (SHSE:688253), the current Current Ratio is 15.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovita Biological Technology Co (SHSE:688253) Overvalued in 2026?
Based on GuruFocus' analysis, Innovita Biological Technology Co stock appears to be overvalued.
The current stock price of ¥58.92 is trading 187.7% above its estimated GF Value™ of ¥20.48.
GuruFocus considers Innovita Biological Technology Co to be Significantly Overvalued.
Key valuation signals for SHSE:688253:
Current Ratio: 15.58 (33% above median its 10-year median of 11.69)
GF Value™: ¥20.48 vs. price of ¥58.92 (187.7% above fair value)
Industry Position: 301.5% above the Biotechnology median (#179 of 1411)
No single metric tells the full story. See the SHSE:688253 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovita Biological Technology Co Business Description
Innovita Biological Technology Co Ltd is a biotechnology company focusing on the research and development, production, and sales of POCT in vitro diagnostic products.
61GF Score
Get the complete analysis for SHSE:688253
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688253 has been successfully added to your 
